Common arthritis drugs reduce systemic Sjögren's disease activity in 24 weeks

Common arthritis drugs reduce systemic Sjögren's disease activity in 24 weeks

A combination of two widely available anti-rheumatic drugs offers the first effective and affordable treatment for patients with Sjögren's disease with systemic disease activity, according to new results from a clinical trial coordinated by UMC Utrecht. The study showed that treatment with leflunomide and hydroxychloroquine reduced disease activity in patients with moderate-to-severe disease while maintaining a favorable safety profile.